Side-by-side · Research reference
BPC-157vsHexarelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2Reviewed9/53 cited
BPhase 1Reviewed19/45 cited
BPC-157
Stable Gastric Pentadecapeptide · Healing
SQ or IM · Local · Once or twice daily
Hexarelin
Hexapeptide GHRP · Cardio-tropic
SQ · Multiple sites · 1–3×/day
01Mechanism of Action
Parameter
BPC-157
Hexarelin
Primary target
VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2014Sikiric 2018
Ghrelin receptor (GHS-R1a) + cardiac CD36Smith 1996Ghigo 1997
Pathway
Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2014
GHS-R1a → Gαq → Ca²⁺ → GH release. CD36 engagement → direct cardio-tropic actionGhigo 1997
Downstream effect
Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018
Strong GH pulse + IGF-1 elevation; cardio-protective effects in animal MI modelsGhigo 1997
Feedback intact?
No known endogenous receptor; mechanism still under investigation
Yes initially; tachyphylaxis with chronic useGhigo 1997
Origin
Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018
Synthetic hexapeptide His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂Smith 1996
Antibody development
—
—
02Dosage Protocols
Parameter
BPC-157
Hexarelin
Standard dose
250–500 mcg / dayHwang 2016
Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.
100–200 mcg per injectionSmith 1996
Frequency
Once or twice daily
Split dosing reported anecdotally for chronic injury.
1–2× per day max (tachyphylaxis with chronic 3× daily)
Lower / starter dose
200 mcg / day
Conservative starter for new users.
50 mcg per dose
Evidence basis
Animal-strong + Phase 2 clinicalSikiric 2018Hwang 2016
Phase 1 / Phase 2 trialsSmith 1996Ghigo 1997
Duration
2–4 weeks (acute injury); 4–8 weeks (chronic)
Anecdotal; no long-term human safety data.
4–8 weeks on / 4–8 weeks off (tachyphylaxis mitigation)
Reconstitution
Bacteriostatic water, 1–2 mL
Bacteriostatic water
Timing
Local SQ to injury site preferred (anecdotal)
Systemic SQ also used; oral bioavailability shown in animal studies.
Pre-sleep + fasted preferred
Half-life
~30 min plasma (estimated)
Tissue half-life longer; mechanism may explain durable effect.
~70 minSemenistaya 2010
04Side Effects & Safety
Parameter
BPC-157
Hexarelin
Injection site reaction
Mild irritation (anecdotal)
—
GI symptoms
None reported in PL-14736 Phase 2
—
Cardiovascular
Not reported
—
Cancer risk
Theoretical concern via VEGF angiogenesis pathwaySikiric 2018
Contraindicated in active malignancy (GH/IGF-1 axis)
Antibody formation
No data (no long-term human trials)
—
Pregnancy / OB
Avoid — insufficient safety data
Avoid
Long-term safety
Unknown beyond Phase 2 trial duration
—
Drug interactions
None established
—
Hunger
—
Strong appetite increase via ghrelin agonism
IGF-1 elevation
—
Strong; monitor with chronic high-dose use
Absolute Contraindications
BPC-157
- ·Pregnancy / breastfeeding
- ·Known active malignancy (theoretical VEGF concern)
Hexarelin
- ·Active malignancy
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Relative Contraindications
BPC-157
- ·History of cancer
- ·Concurrent VEGF inhibitor therapy (theoretical)
- ·Acute thrombotic events
Hexarelin
- ·Untreated diabetes
- ·Severe hyperprolactinemia
05Administration Protocol
Parameter
BPC-157
Hexarelin
1. Reconstitution
Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.
2. Injection site
Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.
SQ — abdomen or thigh. Rotate sites.
3. Timing
No strict timing requirement. Most users dose once or twice daily, often morning + evening.
Pre-sleep + fasted preferred. Cycle on/off to avoid tachyphylaxis.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle
27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
BPC-157
+ TB-500
StrongBPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.
- BPC-157
- 250–500 mcg SQ · daily
- TB-500
- 2 mg SQ · 2× per week
- Primary benefit
- Tendon/ligament/muscle repair via complementary angiogenesis + migration
Hexarelin
+ CJC-1295 (no DAC)
StrongHexarelin (GHRP) + CJC-1295-no-DAC (GHRH analogue) is the higher-amplitude variant of the standard GHRH+GHRP stack. Hexarelin produces a stronger pulse than ipamorelin but with cortisol + prolactin signal — choose this stack for maximum GH amplitude when side-effect tolerance is acceptable. Cycle aggressively.
- Hexarelin
- 100 mcg SQ · pre-sleep
- CJC-1295 (no DAC)
- 100 mcg SQ · same injection
- Primary benefit
- Maximum GH pulse amplitude (with side-effect signal)